LMWH is associated with heparin-induced thrombocytopenia (HIT) incidence compared with UFH?

Study for the Anticoagulation and ACS Exam with tailored flashcards and multiple choice questions, each featuring hints and detailed explanations. Prepare effectively and ensure success on your exam with confidence!

Multiple Choice

LMWH is associated with heparin-induced thrombocytopenia (HIT) incidence compared with UFH?

Explanation:
The key concept is that the risk of heparin-induced thrombocytopenia is lower with low-molecular-weight heparin than with unfractionated heparin. HIT is an immune reaction where antibodies form against complexes of heparin and platelet factor 4, activating platelets and causing thrombocytopenia with a risk of thrombosis. Unfractionated heparin presents a broader mix of longer chains that form larger, more immunogenic PF4-heparin complexes, so HIT occurs more frequently. Low-molecular-weight heparin, being a smaller fragment with more predictable pharmacokinetics, forms less immunogenic complexes, leading to a reduced incidence of HIT. Note that HIT can still occur with LMWH, so clinicians remain vigilant and may switch to a non-heparin anticoagulant if HIT is suspected.

The key concept is that the risk of heparin-induced thrombocytopenia is lower with low-molecular-weight heparin than with unfractionated heparin. HIT is an immune reaction where antibodies form against complexes of heparin and platelet factor 4, activating platelets and causing thrombocytopenia with a risk of thrombosis. Unfractionated heparin presents a broader mix of longer chains that form larger, more immunogenic PF4-heparin complexes, so HIT occurs more frequently. Low-molecular-weight heparin, being a smaller fragment with more predictable pharmacokinetics, forms less immunogenic complexes, leading to a reduced incidence of HIT. Note that HIT can still occur with LMWH, so clinicians remain vigilant and may switch to a non-heparin anticoagulant if HIT is suspected.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy